3D bioprinting has caused enthusiasm in the field of regenerative medicine. The prospect is that in the medium term, 5 to 10 years, it will be possible to deliver printed tissues to surgeons that meet specific demands, from skin, cartilage, bone, to vascular grafts and more complex organs.
The flexibility of our bioprinting technology makes it possible to use a wide variety of cells and materials, making it possible to build tissues from allogeneic cells, which are not the patient’s or autogenous cells, from the patient himself, thus reducing rejections and the need for drugs immunosuppressive.